Response Genetics wins testing contract for lung cancer studies

NCI's Frederick National Laboratory for Cancer Research operations and technical support contractor Leidos Biomedical Research awards the molecular testing contract for ALCHEMIST to Response Genetics (RGDX +3.8%). The contract will run 5 - 6 years and will involve screening thousands of early-stage lung cancer patients for EGFR gene mutations and ALK gene rearrangement.

ALCHEMIST consists of three integrated studies (one screening and two treatment) implemented through the National Clinical Trials Network of the National Cancer Institute.

The specific monetary size is not disclosed, but is referred to as "multimillion."

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs